Immunotherapy has benefitted many patients across several different cancer types by empowering their immune systems to eliminate their tumors. Unfortunately, in the majority of patients, tumors figure out ways to evade the immune system. To decipher how tumors do this, Dr. Susan Kaech is comparing the genetic differences between immunotherapy-resistant tumors and those that respond to immunotherapy. In this way, she aims to systematically identify the genes that may contribute to immunotherapy resistance. After identifying potentially important genes, Dr. Kaech will then determine the ability of each of these genes to cause resistance, and then characterize the mechanisms through which they do so. Overall, her studies will deepen our understanding of how tumor resistance occurs, which could potentially lead to new ways of combining immunotherapies to make them more effective and durable as well as provide a foundation for the development of superior monitoring strategies for patients undergoing immunotherapy.
Funding by CRI for my lab and postdoctoral fellows has allowed us to voyage into studying forms of immunotherapies that operate independently of T cells with the hope of identifying therapies for patients with non-inflammed tumors.
As a Wade F. B. Thompson CLIP Investigator (2014-2017), Dr. Kaech investigated how targeting tumor-associated macrophages (TAMs) might enhance immunotherapy’s effectiveness and improve patient survival.
Projects and Grants
Elucidating cellular and genetic factors associated with tumor resistance to immunotherapies
Salk Institute for Biological Studies | All Cancers | 2017
Enhancing immunotherapy-based cancer treatments through CD40-dependent immunomodulation of the tumor microenvironment
Yale University | Lung Cancer, Melanoma | 2014
Let's spread the word about Immunotherapy! Click to share this page with your community.